

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Chelius Erik C.</u> <hr/> (Last) (First) (Middle) 3000 KENT AVE., SUITE A1-100 <hr/> (Street) WEST LAFAYETTE IN 47906 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 02/07/2018	3. Issuer Name and Ticker or Trading Symbol ENDOCYTE INC [ECYT]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Vice President CMC	5. If Amendment, Date of Original Filed (Month/Day/Year) <hr/> 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	38,159 ⁽¹⁾	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Stock Option (right to buy)	(2)	02/05/2022	Common Stock	14,000	3.64	D
Stock Option (right to buy)	(2)	02/19/2023	Common Stock	15,500	9.86	D
Stock option (right to buy)	(2)	02/06/2024	Common stock	10,850	11.11	D
Stock Option (right to buy)	(2)	02/04/2025	Common Stock	11,568	5.1	D
Stock Option (right to buy)	(3)	02/04/2026	Common Stock	14,062	3.18	D
Stock Option (right to buy)	(4)	02/02/2027	Common Stock	11,413	2.16	D

Explanation of Responses:

- Represents 10,362 shares held directly, 3,516 restricted stock units (RSUs) that will vest 1/2 annually over a period of 2 years beginning 2/4/19, 4,281 RSUs that will vest 1/3 annually over a period of 3 years beginning 2/2/19, and 20,000 RSUs that will vest 1/2 annually over a period of 2 years beginning 10/4/18 in the form of one share of common stock for each RSU.
- Option is fully vested and immediately exercisable.
- Shares subject to the option will vest 1/4 annually over a period of 4 years beginning on 2/4/2017.
- Shares subject to the option will vest 1/4 annually over a period of 4 years beginning on 2/2/18.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

/s/ Beth A. Taylor, Attorney-in-Fact for Erik C. Chelius (power of attorney herewith filed) 02/08/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Limited Power of Attorney Securities Law
Compliance

The undersigned, as an officer or director of Endocyte, Inc. (the "Company"), hereby constitutes and appoints Michael A. Sherman and Beth A. Taylor, and each of them, the undersigned's true and lawful attorney in fact and agent to complete and execute such Forms 144, Forms 3, 4 and 5, Form ID and other forms as such attorney shall in his or her discretion determine to be required or advisable pursuant to Rule 144 promulgated under the Securities Act of 1933 (as amended), Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company, and to do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorney shall deem appropriate. The undersigned hereby ratifies and confirms all that said attorneys in fact and agents shall do or cause to be done by virtue hereof.

This Limited Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 144, Forms 3, 4 and 5 or Forms ID with respect to the undersigned's holdings of and transactions in securities issued by the Company unless earlier revoked by the undersigned in a writing delivered to the foregoing attorneys-in-fact.

This Limited Power of Attorney is executed as of the date set forth below.

/s/ Erik C. Chelius
Signature

Erik C. Chelius
Type or Print Name

Dated: January 14, 2018

Witness:

/s/ Kathleen Chelius
Signature

Kathleen Chelius
Type or Print Name

Dated: January 14, 2018

US.115887916.02